Array BioPharma to Present Clinical Data at the 2008 ACR/ARHP Annual Scientific Meeting

Business Wire, Oct 20, 2008

BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on its p38 inhibitor, ARRY-797 and its MEK inhibitor, ARRY-162, at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, Calif.

[TABLE OMITTED]

The posters will be available as PDFs after they are presented on Array's website: http://www.arraybiopharma.com/PatentsPublications/Default.asp? PBCategoryID=3 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.